NEOMDEXSOL

This brand name is authorized in Nigeria.

Active ingredients

The drug NEOMDEXSOL contains a combination of these active pharmaceutical ingredients (APIs):

1	Dexamethasone UNII 2BP70L44PR - DEXAMETHASONE PHOSPHATE
	Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response.
	Read more about Dexamethasone
2	Neomycin UNII I16QD7X297 - NEOMYCIN
	Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.
	Read more about Neomycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-5724	Eye drops	Neomdexsol Eye Drops SOL_DROPS 0.1%; 0.35% 1 X 5ML	56 RNW-PP-162433 Neomdexsol Eye Drops NEOMYCIN, DEXAMETHASONE PHOSPHATE Active Ingredient: Neomycin 0.35%, Dexamethasone phosphate 0.1% Excipients: dibasic sodium phosphate, disodium edetate, benzalkonium chloride, mannitol, creatinine, sodium metabisulphite, glycerin, sodium sulfoxylate formaldehyde, sodium citrate, hydrogen disodium phosphate, water for injection B4-5724 Drugs Imported Products 15ML Prescription Only Medicine (POM) 9/16/2020 EXPHARLAB LIMITED, 387, AGEGE MOTOR ROAD MUSHIN LAGOS 9030750939 expharlab@exphar.be AHLCON PARENTERALS (INDIA) LIMITED, SP-918, Phase III, Bhiwadi-30101019 Distt, Alwar (Raj), India	06/07/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01CA01	Dexamethasone and antiinfectives	S Sensory organs → S01 Ophthalmologicals → S01C Antiinflammatory agents and antiinfectives in combination → S01CA Corticosteroids and antiinfectives in combination
Discover more medicines within S01CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-5724